Search

1. ESMO
2. Meeting Calendar

ESMO Virtual Plenary: Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in First-Line Recurrent or Metastatic Head & Neck Squamous Cell Carcinoma

• Upcoming Meetings
• Past Meetings
• About ESMO Meetings

Start date

11 Jul 2024

End date

12 Jul 2024

Location

Virtual Meeting

Live on11 Jul 2024 at 18:30 CEST

Add to Calendar

How to Access

Programme

• 11 July 2024
• 12 July 2024

18:30-19:30 CEST

Welcome and introduction, Scientific background and context

Amanda Psyrri, Attikon University Hospital, Athens, Greece

Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from cohort B (CPS less-than 1) of the TACTI-003 study

Robert Metcalf, The Christie NHS Foundation Trust, Manchester, UK

Critical analysis and perspectives

Marc Oliva, Institut Català d’Oncologia (ICO) L’Hospitalet, Barcelona, Spain

AACR Expert Commentary

Jong Chul Park, MGH – Massachusetts General Hospital, Boston, MA USA

Discussion and Q&A (i)

Faculty and online audience

Submit you Abstract

• Submit you Abstract

Related Links

• ESMO Vir